Skip to main content
. 2016 May 21;7(27):41691–41702. doi: 10.18632/oncotarget.9541

Figure 2.

Figure 2

(A) Kaplan–Meier survival curves for relapse free according to MET exon 14 skipping or other known oncogenic drivers in 1635 NSCLC patients; (B) Overall survival according to MET exon 14 skipping or other known oncogenic drivers in 1393 NSCLC patients. Pan-negative indicates EGFR, KRAS, HER2, BRAF, ALK, RET, and MET negative.